Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Paclitaxel; Trastuzumab; Vinorelbine
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors US Oncology Research
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.